Avantor, Inc. (AVTR)
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
- Symbol
- AVTR
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $10.08B
- 52 week range
- 7.26 - 16.05
Valuation
- Share price
- $14.76 (close of 2026-09-23)
- P/E (TTM)
- -18.22x
- Price to book
- 1.80x
- Price to free cash flow
- 22.97x
- Enterprise value
- $13.62B
- Book value per share
- $8.18
Price performance
| Period | Change |
|---|
| 1 day | -2.25% |
| 5 days | -4.40% |
| 1 month | +2.07% |
| 3 months | +56.52% |
| 6 months | +94.47% |
| Year to date | +28.80% |
| 1 year | +20.59% |
| 3 years | -30.08% |
| 5 years | -66.30% |
| All time | +1.79% |
Profitability and growth
- Return on equity
- -9.53%
- Return on invested capital
- -2.69%
- Return on assets
- -4.50%
- Return on capital employed
- -2.36%
- Gross margin
- 32.65%
- Net margin
- -8.09%
- EBITDA margin
- 2.50%
- Revenue growth
- -3.41%
- Net income growth
- -174.52%
- Free cash flow growth
- -28.47%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 4.35%
- Current ratio
- 1.76x
- Net debt to EBITDA
- 30.89x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $6.55B
- Cost of revenue
- $4.41B
- Gross profit
- $2.14B
- EBITDA
- $164.00M
- Net income
- $-530.20M
- Earnings per share
- $-0.78
- Shares outstanding
- 680.60M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $6.55B | $2.14B | $-530.20M | $-0.78 |
| 2024-12-31 | $6.78B | $2.28B | $711.50M | $1.05 |
| 2023-12-31 | $6.97B | $2.36B | $321.10M | $0.48 |
| 2022-12-31 | $7.51B | $2.60B | $686.50M | $1.02 |
| 2021-12-31 | $7.39B | $2.50B | $572.60M | $0.86 |
| 2020-12-31 | $6.39B | $2.08B | $116.60M | $0.09 |
| 2019-12-31 | $6.04B | $1.92B | $37.80M | $-0.84 |
| 2018-12-31 | $5.86B | $1.82B | $-86.90M | $-2.69 |
| 2017-12-31 | $1.25B | $432.80M | $-112.70M | $-2.75 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 32.65% | -8.09% | -9.53% | -2.69% |
| 2024-12-31 | 33.60% | 10.49% | 11.94% | 9.67% |
| 2023-12-31 | 33.93% | 4.61% | 6.11% | 5.77% |
| 2022-12-31 | 34.65% | 9.14% | 14.14% | 8.97% |
| 2021-12-31 | 33.88% | 7.75% | 13.64% | 7.13% |
| 2020-12-31 | 32.54% | 1.82% | 4.36% | 9.44% |
| 2019-12-31 | 31.80% | 0.63% | 1.54% | 7.23% |
| 2018-12-31 | 31.03% | -1.48% | 2.85% | 11.21% |
| 2017-12-31 | 34.70% | -9.03% | 4.30% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $365.40M | $3.92B |
| 2024-12-31 | $261.90M | $3.23B |
| 2023-12-31 | $262.90M | $5.28B |
| 2022-12-31 | $372.90M | $5.92B |
| 2021-12-31 | $301.70M | $6.98B |
| 2020-12-31 | $286.60M | $4.87B |
| 2019-12-31 | $186.70M | $5.02B |
| 2018-12-31 | $184.70M | $6.78B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $495.00M | $46.40M |
| 2024-12-31 | $692.00M | $46.80M |
| 2023-12-31 | $723.60M | $40.50M |
| 2022-12-31 | $710.20M | $45.80M |
| 2021-12-31 | $842.50M | $50.70M |
| 2020-12-31 | $868.20M | $44.10M |
| 2019-12-31 | $302.40M | $67.90M |
| 2018-12-31 | $162.80M | $18.40M |
| 2017-12-31 | $-192.70M | $48.20M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.21
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | $0.19 |
| 2026-04-29 | - | - |
| 2026-02-11 | - | - |
| 2025-10-29 | - | - |
| 2025-08-01 | - | - |
| 2025-07-24 | - | - |
| 2025-04-25 | - | - |
| 2025-04-24 | - | - |
Filings and sources
- Company website
- avantorsciences.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades